Natural Products
Ginsenoside Rd
| Catalog No. | CFN99975 |  |
| CAS No. | 52705-93-8 | |
| Molecular Weight: | 947.2 | |
| Molecular Formula | C48H82O18 | |
| DBs | [PubChem]:134224739 [ChEMBL]:67988 [PCIDB]:30398 |
Standard InChI:
InChI=1S/C48H82O18/c1-22(2)10-9-14-48(8,66-42-39(60)36(57)33(54)26(20-50)62-42)23-11-16-47(7)31(23)24(52)18-29-45(5)15-13-30(44(3,4)28(45)12-17-46(29,47)6)64-43-40(37(58)34(55)27(21-51)63-43)65-41-38(59)35(56)32(53)25(19-49)61-41/h10,23-43,49-60H,9,11-21H2,1-8H3/t23-,24+,25+,26+,27+,28-,29+,30-,31-,32+,33+,34+,35-,36-,37-,38+,39+,40+,41-,42-,43-,45-,46+,47+,48-/m0/s1
Biological Activity
Ginsenoside Rd (Rd), a saponin isolated from the roots of panax notoginseng, Rd has immunological adjuvant activity, and elicits a Th1 and Th2 immune response by regulating production and gene expression of Th1 cytokines and Th2 cytokines.[1]
Ginsenoside-Rd could play a crucial role in enhancing the defence system to counteract the aging process, through regulation of the GSH/GSSG redox status, decreasing in the superoxide dismutase (SOD) and catalase activity in old SAM.[2]
Ginsenoside-Rd treatment shows attenuation of hypertensive cerebrovascular remodeling, the underlying mechanism might be associated with inhibitory effects of ginsenoside-Rd on voltage-independent Ca 2+ entry and BAVSMC proliferation, but not with VDCC-mediated Ca 2+ entry.[3]
Ginsenoside Rd, a -type steroid extracted from , has exhibited an encouraging neuroprotective efficacy in both laboratory and clinical studies, could be as a neuroprotective agent for acute .[4]
Ginsenoside Rd can enhance the proliferation but not affect the differentiation of neural stem cells in vivo and in vitro.[5]
Ginsenoside Rd prevents glutamate-induced apoptosis in rat cortical neurons and may be the potential of voltage-independent Cachannel blockers as new neuroprotective drugs for the prevention of neuronal apoptosis and death induced by cerebral ischaemia.[6]
Product
References
[1] Yang Z, Chen A, Sun H, et al. Vaccine, 2007, 25(1):161-9.
[2] Takako Y, Akiko S, Ju C E. J Pharma Pharmacol, 2004, 56(1):107-13.
[3] Cai B X, Li X Y, Chen J H, et al. Eur J Pharmacol, 2009, 606(1–3):142-9.
[4] Ye R, Gang Z, Liu X. Expert Rev Neuroth, 2013, 13(6):603-13.
[5] Lin T, Liu Y, Shi M, et al. J Ethnopharmacol, 2012, 142(3):754–61.
[6] Li X Y, Liang J, Tang Y B, et al. Clin Exp Pharmacol P , 2010, 37(2):199–204.
[7] Qin H Y, Suo Z R, Wei Y Q. Journal of Southwest University of Science & Technology, 2013, 28(02):92-94.
Product Use Citation
